Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1988 Aug;47(8):634–641. doi: 10.1136/ard.47.8.634

Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting.

C G Kallenberg 1, A A Wouda 1, M H Hoet 1, W J van Venrooij 1
PMCID: PMC1006713  PMID: 3261966

Abstract

Eighty five patients referred because of Raynaud's phenomenon (RP) were followed up for six years. Every two years they were screened for signs and symptoms of connective tissue disease (CTD) according to a protocol, and serum was stored. Initially, 30 patients had primary RP, 16 had one symptom of CTD ('possible CTD'), 18 had two or more symptoms ('probable CTD'), and 21 had definite CTD (14 of whom had scleroderma). Most of the symptoms were related to scleroderma. There was an insidious progression to scleroderma or CRST syndrome (calcinosis, Raynaud's phenomenon, sclerodactyly, telangiectasia): 11 of 46 patients with primary RP or possible CTD developed probable scleroderma (two or more symptoms but not fulfilling all criteria), and seven of 13 patients with probable scleroderma developed definite scleroderma or CRST. The presence of distinct antinuclear antibodies (ANAs) as detected by immunoblotting in patients with primary RP and possible CTD at the start of the study was associated with the evolution of symptoms of CTD (chi 2 = 5.7, p less than 0.01). In patients initially with primary RP or possible CTD the antibody specificities of ANAs as determined by immunoblotting had prognostic value for the development of certain disease entities: anticentromere (CR-19) for CRST (sensitivity 60%, specificity 98%) and antitopoisomerase I (Scl-70 or Scl-86) for scleroderma or probable scleroderma (sensitivity 38%, specificity 100%).

Full text

PDF
634

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Campbell P. M., LeRoy E. C. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum. 1975 May;4(4):351–368. doi: 10.1016/0049-0172(75)90017-7. [DOI] [PubMed] [Google Scholar]
  2. GIFFORD R. W., Jr, HINES E. A., Jr Raynaud's disease among women and girls. Circulation. 1957 Dec;16(6):1012–1021. doi: 10.1161/01.cir.16.6.1012. [DOI] [PubMed] [Google Scholar]
  3. Gerbracht D. D., Steen V. D., Ziegler G. L., Medsger T. A., Jr, Rodnan G. P. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. Arthritis Rheum. 1985 Jan;28(1):87–92. doi: 10.1002/art.1780280114. [DOI] [PubMed] [Google Scholar]
  4. Habets W. J., Berden J. H., Hoch S. O., Van Venrooij W. J. Further characterization and subcellular localization of Sm and U1 ribonucleoprotein antigens. Eur J Immunol. 1985 Oct;15(10):992–997. doi: 10.1002/eji.1830151006. [DOI] [PubMed] [Google Scholar]
  5. Harper F. E., Maricq H. R., Turner R. E., Lidman R. W., Leroy E. C. A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. Am J Med. 1982 Jun;72(6):883–888. doi: 10.1016/0002-9343(82)90846-4. [DOI] [PubMed] [Google Scholar]
  6. Kallenberg C. G., Pastoor G. W., Wouda A. A., The T. H. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis. 1982 Aug;41(4):382–387. doi: 10.1136/ard.41.4.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kallenberg C. G., Wouda A. A., The T. H. Systemic autoimmune disease and Raynaud's phenomenon: a common, immunologically mediated, vascular basis? Neth J Med. 1984;27(9):322–326. [PubMed] [Google Scholar]
  8. Kallenberg C. G., Wouda A. A., The T. H. Systemic involvement and immunologic findings in patients presenting with Raynaud's phenomenon. Am J Med. 1980 Nov;69(5):675–680. doi: 10.1016/0002-9343(80)90417-9. [DOI] [PubMed] [Google Scholar]
  9. Kurata N., Tan E. M. Identification of antibodies to nuclear acidic antigens by counterimmunoelectrophoresis. Arthritis Rheum. 1976 May-Jun;19(3):574–580. doi: 10.1002/art.1780190309. [DOI] [PubMed] [Google Scholar]
  10. Maricq H. R., Weinrich M. C., Keil J. E., LeRoy E. C. Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire. J Chronic Dis. 1986;39(6):423–427. doi: 10.1016/0021-9681(86)90109-8. [DOI] [PubMed] [Google Scholar]
  11. Maul G. G., French B. T., van Venrooij W. J., Jimenez S. A. Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase. Proc Natl Acad Sci U S A. 1986 Jul;83(14):5145–5149. doi: 10.1073/pnas.83.14.5145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nimelstein S. H., Brody S., McShane D., Holman H. R. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore) 1980 Jul;59(4):239–248. [PubMed] [Google Scholar]
  13. Olsen N., Nielsen S. L. Prevalence of primary Raynaud phenomena in young females. Scand J Clin Lab Invest. 1978 Dec;38(8):761–764. doi: 10.1080/00365517809104884. [DOI] [PubMed] [Google Scholar]
  14. Sharp G. C., Irvin W. S., Tan E. M., Gould R. G., Holman H. R. Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972 Feb;52(2):148–159. doi: 10.1016/0002-9343(72)90064-2. [DOI] [PubMed] [Google Scholar]
  15. Shero J. H., Bordwell B., Rothfield N. F., Earnshaw W. C. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science. 1986 Feb 14;231(4739):737–740. doi: 10.1126/science.3003910. [DOI] [PubMed] [Google Scholar]
  16. TUFFANELLI D. L., WINKELMANN R. K. Systemic scleroderma, A clinical study of 727 cases. Arch Dermatol. 1961 Sep;84:359–371. doi: 10.1001/archderm.1961.01580150005001. [DOI] [PubMed] [Google Scholar]
  17. Tan E. M. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol. 1982;33:167–240. doi: 10.1016/s0065-2776(08)60836-6. [DOI] [PubMed] [Google Scholar]
  18. Tan E. M., Rodnan G. P., Garcia I., Moroi Y., Fritzler M. J., Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum. 1980 Jun;23(6):617–625. doi: 10.1002/art.1780230602. [DOI] [PubMed] [Google Scholar]
  19. Wouda A. A. Raynaud's phenomenon. Photoelectric plethysmography of the fingers of persons with and without Raynaud's phenomenon during cooling and warming up. Acta Med Scand. 1977;201(6):519–523. [PubMed] [Google Scholar]
  20. van Venrooij W. J., Stapel S. O., Houben H., Habets W. J., Kallenberg C. G., Penner E., van de Putte L. B. Scl-86, a marker antigen for diffuse scleroderma. J Clin Invest. 1985 Mar;75(3):1053–1060. doi: 10.1172/JCI111767. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES